DOCSLIB.ORG

Meeting Program SID 2019 ANNUAL MEETING

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Meeting Program SID 2019 ANNUAL MEETING 2019 Annual Meeting Scientific 2019 Annual Meeting Program Chairs, Committee Committee on Education Members, and Reviewers Chairs and Committee CHAIRS Members Dan Kaplan, MD/PhD, University of Pittsburgh CHAIRS Ethan Lerner, MD/PhD, Mass General Hospital Heidi Kong, MD, National Insitutes of Health Todd Ridky, MD/PhD, University of Pennsylvania COMMITTEE MEMBERS Lloyd Miller, MD/PhD, Johns Hopkins University COMMITTEE MEMBERS Kevin Wang, MD/PhD, Stanford University My Mahoney, PhD, Thomas Jefferson University Spiro Getsios, PhD, Aspect Biosystems Alexander Marneros, MD/PhD, Harvard University Peggy Myung, MD/PhD, Yale University Robert Dellavalle, MD/PhD, University of Colorado Marjana Tomic-Canic PhD, University of Miami Amanda MacLeod, MD, Duke University Vladimir Botchkarev, MD/PhD, Boston University Cristina de Guzman Strong, PhD, Washington University-St. Louis Tissa Hata, MD, University of California, San Diego Maryam Asgari, MD, Massachusetts General Hospital Ken Tsai, MD/PhD, Moffitt Cancer Center and Paul Nghiem, MD/PhD, University of Washington Research Institute Richard Granstein, MD, Weill Cornell Medical School Sarah Millar, PhD, Mt. Sinai Medical School Matthew Vesley, MD/PhD, Yale University REVIEWERS Anna Di Nardo, MD/PhD Jennifer Gill, MD/PhD, University of Texas Southwestern Carolyn Lee, MD/PhD Jonathan Silverberg, MD/PhD ACKNOWLEDGEMENTS Bogi Andersen, MD The organizers of the 2019 SID Annual Meeting gratefully Kavita Sarin, MD/PhD acknowledge the sponsors, exhibitors, and participants whose Peter Koch, PhD Tiffany C. Scharschmidt, MD attendance has helped to make this meeting possible. Joseph Merola, MD Sakeen Kashem, MD/PhD Thomas Hultsch, MD Amanda MacLeod, MD Liang Deng, MD/PhD Ya-Chieh Hsu, PhD Crystal Aguh, MD Katherine Radek, PhD Paul Nghiem, MD/PhD Alicia Mathers, PhD Raymond Cho, MD Zelma Chiesa, MD Anna Mandinova, MD/PhD Brian Capell, MD/PhD Ryan R. Driskell, PhD Philip Scumpia, MD/PhD Elizabeth Wallace, MD Sarina Elmariah, MD/PhD Leigh Nattkemper, PhD Taihao Quan, MD/PhD Nancy Thomas, MD/PhD Sunny Wong, PhD Benjamin Chong, MD Elizabeth A. Grice, PhD Brian Kim, MD Aaron Drucker, MD Emma Gutman-Yassky, MD/PhD www.sidnet.org Nicole Ward, PhD Niroshana Anandasabapathy, MD/PhD Donald Glass, MD/PhD 2 SID 2019 ANNUAL MEETING Welcome to Chicago I’d like to personally welcome each of you to the Society We anticipate a record number of attendees and for Investigative Dermatology (SID) Annual Meeting. This presenters, hailing from nearly 30 countries, and year marks our 77th meeting in our 81st year. Chicago representing specialties and disciplines ranging is a fitting place for our global community to convene. from Dermatology and Immunology, to Biomedical Chicago has been central to the growth and history of Engineering, Cell Biology and Genetics. We remain the United States. It’s central location upon waterways committed to nurturing a diverse community of skin and connecting railroads propelled its economic growth. biologists who can exchange information during our It bridges the eastern part of the US with the western educational sessions in order to accelerate discovery. As half. Furthermore, events in Chicago have bridged our we complete the second decade of the 21st Century, we earlier history with contemporary events. One of Illinois look to our host city to inspire us to cultivate a culture of most famous citizens, Abraham Lincoln was nominated collegiality, inclusion and maintain our collective spirit of as a candidate for President in 1860 at the Republican inquiry. I am so thrilled that you are here. Convention hosted in Chicago, initially ushering in a transformational process of emancipation and inclusion, still a work in process today. Like Chicago, the SID also serves as a connector and bridge. The SID is a central knowledge hub for interested Robert A. Swerlick, MD in the study of skin health and disease, connecting basic SID President researchers, clinicians, and trainees. The global community catalyzed by the SID continues to grow and evolve and the SID maintains its commitment to serve as the premier forum for the exchange of knowledge, advancing the cutting edge of the science cutaneous biology and skin therapeutics. 3 SID 2019 ANNUAL MEETING Meeting-At-A-Glance TUESDAY, MAY 7, 2019 ——————–––––—————————–––––––——————————————————–––––––— 8:45 AM — 9:45 AM ——————–––––—————————–––––––——————————————————–––––––— Plenary Session I 12:00 PM — 7:30 PM INTERNATIONAL BALLROOM NORTH Satellite Symposium on Skin Epigenetics ——————–––––—————————–––––––——————————————————–––––––— CONTINENTAL BALLROOM A 9:45 AM — 10:15 AM ——————–––––—————————–––––––——————————————————–––––––— Julius Stone Lecture: Skin Microbiota in Tissue 4:00 PM — 7:00 PM Immunity and Repair Resident/PhD Retreat Sessions: By Invitation Only YASMINE BELKAID, PHD MARQUETTE ROOM INTERNATIONAL BALLROOM NORTH ——————–––––—————————–––––––——————————————————–––––––— ——————–––––—————————–––––––——————————————————–––––––— 10:15 AM — 10:45 AM William Montagna Lecture: Regulatory T cells in Skin WEDNESDAY, MAY 8, 2019 MICHAEL D. ROSENBLUM, MD/PHD ——————–––––—————————–––––––——————————————————–––––––— INTERNATIONAL BALLROOM NORTH 6:45 AM — 7:30 AM ——————–––––—————————–––––––——————————————————–––––––— 10:45 AM — 12:45 PM Resident/PhD Retreat Breakfast: By Invitation Only JOLIET ROOM Poster Session I/Coffee Break ——————–––––—————————–––––––——————————————————–––––––— STEVENS SALONS B/C/D SEE PAGE 13 FOR POSTER NUMBER LISTINGS 7:30 AM — 12:00 PM ——————–––––—————————–––––––——————————————————–––––––— Resident Retreat Program: By Invitation Only 11:15 AM – 12:45 PM MARQUETTE ROOM ——————–––––—————————–––––––——————————————————–––––––— Aclaris Sponsored Symposium: HiJAKing Topical Therapies for 7:30 AM — 12:00 PM New Indications in Dermatology PhD Retreat Program: By Invitation Only INTERNATIONAL BALLROOM NORTH ASTORIA ROOM ——————–––––—————————–––––––——————————————————–––––––— ——————–––––—————————–––––––——————————————————–––––––— 11:15 AM — 12:15 PM 11:00 AM — 7:00 PM Selected ePoster Discussions I On-Site Registration SEE PAGES 51-55 FOR ROOM LISTINGS 8TH ST. S. REGISTRATION AREA ——————–––––—————————–––––––——————————————————–––––––— ——————–––––—————————–––––––——————————————————–––––––— 1:30 PM — 4:00 PM 2:00 PM — 4:30 PM Concurrent Minisymposium 1: Adaptive and Auto-Immunity Translational Science Symposium: Single Cell Analysis: INTERNATIONAL BALLROOM NORTH ——————–––––—————————–––––––——————————————————–––––––— Insights into Disease 1:30 PM — 4:00 PM INTERNATIONAL BALLROOM NORTH ——————–––––—————————–––––––——————————————————–––––––— Concurrent Minisymposium 2: Genetic Disease, Gene 2:00 PM — 4:30 PM Regulation and Gene Therapy Advancing Innovation in Dermatology: CONTINENTAL BALLROOM A ——————–––––—————————–––––––——————————————————–––––––— Translational Research and Academic - Industry Partnership 1:30 PM — 4:00 PM INTERNATIONAL BALLROOM SOUTH ——————–––––—————————–––––––——————————————————–––––––— Concurrent Minisymposium 3: Growth Factors, Cell Adhesion 4:30 PM — 5:30 PM and Matrix Biology Clinical/Outcomes Scholars: Diving Skin-Deep into CONTINENTAL BALLROOM C ——————–––––—————————–––––––——————————————————–––––––— Databases and Inflammation 1:30 PM — 4:00 PM INTERNATIONAL BALLROOM NORTH ——————–––––—————————–––––––——————————————————–––––––— Concurrent Minisymposium 4: Interventional Studies, Clinical 5:30 PM — 5:45 PM and Patient Reported Outcomes President’s Welcome INTERNATIONAL BALLROOM SOUTH ROBERT A. SWERLICK, MD ——————–––––—————————–––––––——————————————————–––––––— INTERNATIONAL BALLROOM NORTH 1:30 PM — 4:00 PM ——————–––––—————————–––––––——————————————————–––––––— Concurrent Minisymposium 5: Photobiology 5:45 PM — 6:15 PM CONTINENTAL BALLROOM B Naomi M. Kanof Lecture: The Significance of ——————–––––—————————–––––––——————————————————–––––––— Dermatology Outcomes Research – Beyond the 1:30 PM — 4:00 PM Concurrent Minisymposium 6: Interdisciplinary Spotlight: H-Index and Impact Factor Disease Models SUEPHY CHEN, MD/MS WALDORF ROOM INTERNATIONAL BALLROOM NORTH ——————–––––—————————–––––––——————————————————–––––––— ——————–––––—————————–––––––——————————————————–––––––— 4:15 PM — 4:45 PM 6:30 PM — 8:30 PM State-of-the-Art Plenary Lecture I: Welcome Reception NORMANDIE LOUNGE Large-Scale Regeneration in the Skin ——————–––––—————————–––––––——————————————————–––––––— MAKSIM PLIKUS, PHD INTERNATIONAL BALLROOM NORTH ——————–––––—————————–––––––——————————————————–––––––— 4:45 PM — 5:15 PM THURSDAY, MAY 9, 2019 State-of-the-Art Plenary Lecture II: ——————–––––—————————–––––––——————————————————–––––––— Immune Regulation of Skin Inflammation and Itch 7:00 AM — 6:00 PM BRIAN KIM, MD/MTR On-Site Registration INTERNATIONAL BALLROOM NORTH 8TH ST. S. REGISTRATION AREA ——————–––––—————————–––––––——————————————————–––––––— ——————–––––—————————–––––––——————————————————–––––––— 5:15 PM — 5:30 PM 7:30 AM — 8:30 AM LEO Foundation Award Irvin H. Blank Forum I: INTERNATIONAL BALLROOM NORTH Extracellular Vesicles in Cutaneous Homeostasis and Disease ——————–––––—————————–––––––——————————————————–––––––— INTERNATIONAL BALLROOM NORTH 7:00 PM — 10:30 PM ——————–––––—————————–––––––——————————————————–––––––— Social Event MUSEUM OF SCIENCE AND INDUSTRY ——————–––––—————————–––––––——————————————————–––––––— 4 SID 2019 ANNUAL MEETING Meeting-At-A-Glance FRIDAY, MAY 10, 2019 ——————–––––—————————–––––––——————————————————–––––––— ——————–––––—————————–––––––——————————————————–––––––— 2:45 PM — 5:15 PM 7:00 AM — 7:00 PM Concurrent Minisymposium 11: Pharmacology
Recommended publications
  • Case Study of Nestlé1

    Case Study of Nestlé1

    CASE STUDY OF NESTLÉ1 INDEX PART A 1. Introduction 3 2. History 3 3. Industry Analysis and Competitors 5 3.1 Challenges of the food and beverage industry 6 3.2 Sales evolution of the industry 6 3.3 Qualitative Analysis: SWOT industry 8 3.4 Main competitors 9 3.5 Market Share 9 4. Business Model 10 4.1 Mission 10 4.2 Distinctive Factors 10 4.3 Corporate Governance 11 4.4 Corporate Social Responsibility 11 4.5 Segmentation of products 13 5. Questions 13 6. Bibliography 13 7. Notes 14 1 Case written by Clara Aguilar, Cristina Hey, Laura Plaza and Sara Zayas and supervised by Oriol Amat, BSM Universitat Pompeu Fabra, 2018 8. Annex 14 8.1 Balance Sheet 14 8.2 Income Statement 17 8.3 Cash Flow Statement 18 8.4 Ratios 20 PART B 1. Answer to the Questions Raised 22 2 PART A 1. INTRODUCTION “Nestlé” is a Swiss multinational food and beverage company whose business started in 1866. It is one of the largest food companies in the world, with presence in 191 countries, and more than 2,000 brands. Some of these are globally iconic while others are just regional, presenting a great variety of products, such as tea, coffee, bottled water, medical and baby food, breakfast cereals, and lots more. It is a well-known company world-wide, specially because of Nestlé milk chocolate bar, which is one of the most famous products. The company focuses on the production and supply of great quality and healthy food products. Nestle has a huge portfolio and is seen as an enormous competitor across the food industries.
  • Financial Statements 2018

    Financial Statements 2018

    Financial Statements 2018 Consolidated Financial Statements of the Nestlé Group 2018 152nd Financial Statements of Nestlé S.A. Consolidated Financial Statements of the Nestlé Group 2018 Consolidated Financial Statements of the Nestlé Group 2018 63 65 Principal exchange rates 160 Statutory Auditor’s Report – Report on the Audit of the 66 Consolidated income statement for Consolidated Financial Statements the year ended December 31, 2018 166 Financial information – 5 year review 67 Consolidated statement of comprehensive income for the year 168 Companies of the Nestlé Group, joint ended December 31, 2018 arrangements and associates 68 Consolidated balance sheet as at December 31, 2018 70 Consolidated cash fl ow statement for the year ended December 31, 2018 71 Consolidated statement of changes in equity for the year ended December 31, 2018 73 Notes 73 1. Accounting policies 77 2. Scope of consolidation, acquisitions and disposals of businesses, assets held for sale and acquisitions of non-controlling interests 83 3. Analyses by segment 93 4. Net other trading and operating income/ (expenses) 94 5. Net fi nancial income/(expense) 95 6. Inventories 7. Trade and other receivables/payables 97 8. Property, plant and equipment 101 9. Goodwill and intangible assets 107 10. Employee benefi ts 117 11. Provisions and contingencies 119 12. Financial instruments 134 13. Taxes 137 14. Associates and joint ventures 139 15. Earnings per share 140 16. Cash fl ow statement 143 17. Equity 148 18. Transactions with related parties 150 19. Guarantees 20. Effects
  • Corporate Governance Report 30 June 2008

    Corporate Governance Report 30 June 2008

    Corporate Governance Report 30 June 2008 Board of Directors Executive Board Contents Preliminary remarks 3 1. Board of Directors 4 1.1 Members of the Board of Directors 4 1.2. Professional background and other activities and functions 6 1.3 Cross-involvement 8 1.4 Internal organisational structure 9 2. Executive Board 12 2.1 Members of the Executive Board 12 2.2. Professional background and other activities and functions 14 General Organisation of Nestlé S.A. 15 Situation at 30 June 2008 © 2008, Nestlé S.A., Cham and Vevey (Switzerland) Concept: Nestlé S.A., Group Governance, Vevey (Switzerland) Design: Nestec Ltd., Corporate Identity and Design, Vevey (Switzerland) 2 Nestlé | Corporate Governance Report June 2008 Preliminary remarks Nestlé S.A. publishes a full Corporate Governance Report, including a separate Compensation Report, which forms an integral part of the annual Management Report. We therewith comply with the requirements of the SWX Swiss Exchange (SWX) and its Corporate Governance Directive. The present document is a partial update of the Nestlé Corporate Governance Report 2007, indicating changes occurred on the Board of Directors and the Executive Board up to 30 June 2008. The annual Management Report is available on-line as a PDF file at http://www.nestle.com in English, French and German. Copies can be ordered at: http://www.nestle.com/MediaCenter/Order. Contact for Media: Nestlé S.A. Corporate Media Relations Avenue Nestlé 55 CH - 1800 Vevey (Switzerland) tel. +41 (0)21 924 22 00 fax +41 (0)21 922 63 34 e-mail: [email protected] Contact for Investors: Nestlé S.A.
  • Nestlé's Winning Formula for Brand Management

    Nestlé's Winning Formula for Brand Management

    Feature By Véronique Musson Nestlé’s winning formula for brand management ‘Enormous’ hardly begins to describe the trademark that develop products worldwide and are managed from our portfolio of the world’s largest food and drink company headquarters in Vevey, Switzerland or St Louis in the United States,” he explains. So eight trademark advisers, also based in Vevey, advise one – and the workload involved in managing it. But when or more strategic business units on the protection of strategic it comes to finding the best solutions to protect these trademarks, designs and copyrights, while one adviser based in St very valuable assets, Nestlé has found that what works Louis advises the petcare strategic business unit on trademarks and best for it is looking for the answers in-house related issues, as the global petcare business has been managed from St Louis since the acquisition of Ralston Purina in 2001. In parallel, 16 regional IP advisers spread around the world advise the Nestlé Imagine that you start your day with a glass of VITTEL water operating companies (there were 487 production sites worldwide at followed by a cup of CARNATION Instant Breakfast drink. Mid- the end of 2005) on all aspects of intellectual property, including morning you have a cup of NESCAFÉ instant coffee and snack on a trademarks, with a particular focus on local marks. The trademark cheeky KIT KAT chocolate bar; lunch is a HERTA sausage with group also includes a dedicated lawyer in Vevey who manages the BUITONI pasta-and-sauce affair, finished off by a SKI yogurt.
  • Meeting Program SID 2019 ANNUAL MEETING

    Meeting Program SID 2019 ANNUAL MEETING

    Meeting Program SID 2019 ANNUAL MEETING 2019 Annual Meeting Scientific 2019 Annual Meeting Program Chairs, Committee Committee on Education Members, and Reviewers Chairs and Committee CHAIRS Members Dan Kaplan, MD/PhD, University of Pittsburgh CHAIRS Ethan Lerner, MD/PhD, Mass General Hospital Heidi Kong, MD, National Insitutes of Health Todd Ridky, MD/PhD, University of Pennsylvania COMMITTEE MEMBERS Lloyd Miller, MD/PhD, Johns Hopkins University COMMITTEE MEMBERS Kevin Wang, MD/PhD, Stanford University My Mahoney, PhD, Thomas Jefferson University Spiro Getsios, PhD, Aspect Biosystems Alexander Marneros, MD/PhD, Harvard University Peggy Myung, MD/PhD, Yale University Robert Dellavalle, MD/PhD, University of Colorado Marjana Tomic-Canic PhD, University of Miami Amanda MacLeod, MD, Duke University Vladimir Botchkarev, MD/PhD, Boston University Cristina de Guzman Strong, PhD, Washington University-St. Louis Tissa Hata, MD, University of California, San Diego Maryam Asgari, MD, Massachusetts General Hospital Ken Tsai, MD/PhD, Moffitt Cancer Center and Paul Nghiem, MD/PhD, University of Washington Research Institute Richard Granstein, MD, Weill Cornell Medical School Sarah Millar, PhD, Mt. Sinai Medical School Matthew Vesley, MD/PhD, Yale University REVIEWERS Anna Di Nardo, MD/PhD Jennifer Gill, MD/PhD, University of Texas Southwestern Carolyn Lee, MD/PhD Jonathan Silverberg, MD/PhD ACKNOWLEDGEMENTS Bogi Andersen, MD The organizers of the 2019 SID Annual Meeting gratefully Kavita Sarin, MD/PhD acknowledge the sponsors, exhibitors, and participants whose Peter Koch, PhD Tiffany C. Scharschmidt, MD attendance has helped to make this meeting possible. Joseph Merola, MD Sakeen Kashem, MD/PhD Thomas Hultsch, MD Amanda MacLeod, MD Liang Deng, MD/PhD Ya-Chieh Hsu, PhD Crystal Aguh, MD Katherine Radek, PhD Paul Nghiem, MD/PhD Alicia Mathers, PhD Raymond Cho, MD Zelma Chiesa, MD Anna Mandinova, MD/PhD Brian Capell, MD/PhD Ryan R.
  • Teri Melese, Ph.D

    Teri Melese, Ph.D

    Prepared: 02/015 University of California, San Diego Curriculum Vitae Name: Teri Melese, Ph.D Current Position: UCSD Assistant Vice Chancellor, Industry Research Alliances Adjunct Associate Professor, Department of Medicine and Rady School of Management Last Position Held: Adjunct Associate Professor UCSF Department of Medicine, School of Medicine, 2005-2012 UCSF Dean’s Office: Director of Business Strategy and Development, School of Medicine UCSF Helen Diller Comprehensive Cancer Center Executive Committee: Associate Director for Strategic Alliances Address: University of California, San Diego Office of Research Affairs 9500 Gilman Drive #0910 La Jolla, CA 92093-0043 Tel: (858) 822-5247 mobile: (408) 373-3651 [email protected] Education: 1975-77 University of California, Berkeley A.B. Neurobiology/ Literature 1977-82 University of California, San Francisco Ph.D. Regents Fellow 1982-86 University of California, Los Angeles Postdoctoral Fellow Biochemistry 1986-87 University of California, Los Angeles American Cancer Sr. Research Fellow Molecular Biology Principal Positions Held: 1988-92 Columbia University, New York Assistant Professor Biological Sciences 1993-97 Columbia University, New York Associate Professor Biological Sciences 1997-99 Columbia University, New York Adjunct Associate Professor Biological Sciences 1997-01 Iconix Pharmaceuticals Mountain View Founding Member & Director Chemical Genomics 2001-2012 University of California, San Francisco Adjunct Full Professor Step II Medicine Present University of California, San Diego
  • 2018 IID Meeting, Orlando, Florida

    2018 IID Meeting, Orlando, Florida

    May 16-19, 2018 MEETING PROGRAM Rosen Shingle Creek Resort Orlando, Florida www.IID2018.org IID 2018 MEETING IID 2018 Program Chairs and Final Reviewers ESDR - Program Chairs JSID - Program Chairs SID - Program Chairs Michel Gilliet, MD Manabu Fujimoto, MD Nicole Ward, PhD Matthias Schmuth, MD Manabu Ohyama, MD/PhD Victoria Werth, MD ESDR – Final Reviewers JSID – Final Reviewers SID – Final Reviewers Hervé Bachelez, MD/PhD Riichiro Abe, MD/PhD Vladimir Botchkarev, MD/PhD Leopold Eckhart, PhD Manabu Fujimoto, MD Spiro Getsios, PhD Menno de Rie, MD/PhD Minoru Hasegawa, MD Daniel Kaplan, MD/PhD Bernhard Homey, MD Hironobu Ihn, MD/PhD Ethan Lerner, MD/PhD David Kelsell, PhD Kenji Kabashima, MD/PhD Lloyd Miller, MD/PhD Lionel Larue, PhD Takuro Kanekura, MD/PhD Peggy Myung, MD/PhD Caterina Missero, PhD Norito Katoh, PhD Marjana Tomic-Canic, PhD Edel O’Toole, PhD Tatsuyoshi Kawamura, MD/PhD Kevin Wang, MD/PhD Ralf Paus, MD/PhD Akiharu Kubo, MD/PhD Nicole Ward, PhD Sirkku Peltonen, MD/PhD Akimichi Morita, MD/PhD Victoria Werth, MD Neil Rajan, MD/PhD Manabu Ohyama, MD/PhD Martin Steinhoff, MD/PhD Ryuhei Okuyama, MD/PhD Marta Szell, DSc Tamio Suzuki, MD/PhD Thomas Werfel, MD Katsuto Tamai, MD/PhD Peter Wolf, MD Akemi Yamamoto, MD/PhD European Society for Japanese Society for Society for Investigative Dermatological Research Investigative Dermatology Dermatology Rue Cingria 7, Geneva 5F, 4-1-4 Hongo, Bunkyo-ku, Tokyo 526 Superior Avenue East, Suite 340 Switzerland, 1205 113-0033, Japan Cleveland, Ohio 44114, USA Tel: +41 22 321 48 90 Tel: +81-3-3830-0068 Tel: +01 216-579-9300 Email: [email protected] Email: [email protected] Email: [email protected] Web: www.esdr.org Web: www.jsid.org Web: www.sidnet.org ACKNOWLEDGEMENTS The organizers of IID 2018 gratefully acknowledge the many exhibitors and sponsors whose attendance has helped make this meeting possible.
  • Molecular Chaperones in Cancer

    Molecular Chaperones in Cancer

    CNIO - SPANISH”LA CAIXA”NATIONAL CANCER FOUNDATION RESEARCH CENTRE FRONTIERS MEETINGS 2017 Madrid 2nd- 4th May 2017 MOLECULAR CHAPERONES IN CANCER IN MEMORY OF SUSAN LINDQUIST Organisers Nabil Djouder Spanish National Cancer Research Centre (CNIO), Madrid, Spain Wilhelm Krek Institute for Molecular Health Sciences Zurich, Switzerland Paul Workman The Institute of Cancer Research London, UK Xiaohong Helena Yang Cancer Cell Cambridge, US EXCELENCIA MINISTERIO DE ECONOMÍA, INDUSTRIA SEVERO Y COMPETITIVIDAD OCHOA CNIO - SPANISH”LA CAIXA”NATIONAL CANCER FOUNDATION RESEARCH CENTRE FRONTIERS MEETINGS 2017 Madrid 2nd- 4th May 2017 MOLECULAR CHAPERONES IN CANCER CNIO - SPANISH”LA CAIXA”NATIONAL CANCER FOUNDATION RESEARCH CENTRE FRONTIERS MEETINGS 2017 Madrid 2nd- 4th May 2017 MOLECULAR CHAPERONES IN CANCER Summary 07 PROGRAMME 19 KEYNOTE LECTURE 23 SESSIONS 23 S #1 PROTEIN QUALITY CONTROL 31 S #2 FOLDING, MISFOLDING AND AGGREGATION 41 S #3 STRESS MECHANISMS IN CANCER 49 S #4 CHAPERONES IN CANCER 59 S #5 TARGETING CHAPERONES: CHAPERONOTHERAPY 67 CLOSING LECTURE 69 ORGANISERS AND SPEAKERS’ BIOGRAPHIES 99 POSTER SESSIONS 119 Previous CNIO Frontiers Meetings and CNIO Cancer Conferences 05 CNIO - SPANISH”LA CAIXA”NATIONAL CANCER FOUNDATION RESEARCH CENTRE FRONTIERS MEETINGS 2017 Madrid 2nd- 4th May 2017 MOLECULAR CHAPERONES IN CANCER PROGRAMME 07 PROGRAMME Madrid 2nd- 4th May 2017 MOLECULAR CHAPERONES IN CANCER Venue: Spanish National Cancer Research Centre – CNIO Auditorium, Madrid, Spain Chairpersons and organizing committee: Nabil Djouder, Spanish National Cancer Research Centre, Madrid, Spain Wilhelm Krek, Institute for Molecular Health Sciences, ETH, Zurich, Switzerland Paul Workman, The Institute of Cancer Research, London, UK Xiaohong Helena Yang, Cancer Cell, Cambridge, USA Rationale: Molecular chaperones play key roles in the folding, stability and activity of proteins in normal cell homeostasis and disease pa- thology, including cancer.
  • New Frontiers

    New Frontiers

    PROGRAM & BOOK OF ABSTRACTS JUNE 13-16, 2009 • PORTLAND, OREGON New Frontiers Children’s Tumor FoundaTION 95 PINE STREET, 16TH FLOOR, NEW YORK, NY 10005 | WWW.CTF.ORG | 212.344.6633 Dear NF Conference Attendees: On behalf of the Children’s Tumor Foundation, welcome to the 2009 NF Conference: New Frontiers. The theme references the meeting content and also Portland itself, historically a gateway port of the Pacific North West. The urban setting offers a ‘new frontier’ in comparison to the mountain and beach locales of past NF Conferences, but one which we feel you will enjoy. Portland is an easy-going city offering history, beauty and relaxation – features encapsulated in our host hotel The Nines, itself a part of the tapestry of Portland history, renovated from the former landmark Meier & Frank department store. The last year has seen major NF research advances. The dovetailing of discovery, translation and the clinic can be seen throughout the meeting. We are firmly in the age of NF clinical trials and proud that the Children’s Tumor Foundation is part of this advance: in 2009 we funded our first two pilot Clinical Trial Awards. We continue to build a pipeline of candidate NF drug therapies through the Foundation’s multi-center NF Preclinical Consortium and the seed grant Drug Discovery Initiative (DDI) program. Through these translational initiatives we are cultivating NF collaborations with the biotechnology and pharmaceutical sector, a critical factor in moving NF research forward to the clinic. At the same time, basic research advances continue, such as in the unraveling of schwannomatosis.
  • In the United States District Court for the District of Delaware

    In the United States District Court for the District of Delaware

    IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE TRUINJECT CORP., ) ) Plaintiff, ) C.A. No. 19-00592-LPS-JLH ) v. ) ) GALDERMA, S.A., GALDERMA ) LABORATORIES, L.P., NESTLÉ SKIN ) Jury Trial Demanded HEALTH, INC., ) ) Defendants. ) ) CORRECTED SECOND AMENDED COMPLAINT I. EXECUTIVE SUMMARY A. GABRIELLE RIOS SEES A MARKET NEED FOR TRUINJECT 1. Ms. Gabrielle Rios (“Ms. Rios”), the CEO of Plaintiff Truinject Corporation (“Truinject”) in this matter, worked at LexisNexis after college as an account manager. As an account manager, she learned how to use LexisNexis and other search engines to research news stories, press releases and other information she needed for her business. After LexisNexis she worked at Allergan, where she marketed neurotoxins and dermal fillers to medical providers for therapeutic and cosmetic injections. Allergan’s popular Botox product was among the neurotoxins she marketed at Allergan. Botox accounts for roughly half (50%) of the neurotoxin market, and two other companies—Merz and Galderma—sell products that account for most of the rest. Botox and other neurotoxins and dermal fillers1 typically are injected with syringes into patients’ faces and/or other sensitive parts of the body. 1 Dermal fillers are substances that add volume under a patient’s skin; neurotoxins are substances that relax muscles to smooth the overlying skin. Defendant Galderma Labs sells such products Truinject Corp.'s Corrected SECOND AMENDED COMPLAINT - as a matter of right(613629.2).docx 2. While marketing neurotoxins and fillers at Allergan, Ms. Rios worked with doctors and other medical providers who lacked advanced training in using neurotoxins and fillers safely when performing injections.
  • Blue Light Special Photon-Tastic Medicine Over the Transom

    Blue Light Special Photon-Tastic Medicine Over the Transom

    UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE | SPRING 2017 PITTMED BLUE LIGHT SPECIAL PHOTON-TASTIC MEDICINE OVER THE TRANSOM NALOXONE AWARENESS capabilities, getting it to people who are at high RECENT MAGAZINE HONORS The article “Stepping off the Path to Hell” (Fall risk of overdose. Efforts such as these reduce the Carnegie Science Center 2016) was a timely description of the opioid stigma of addiction and substance abuse as they 2016 Science Communicator over-prescribing and overdose epidemic in our give many people a second chance. Honorable Mention, Robyn K. Coggins country. In your coverage of the many efforts that University of Pittsburgh clinicians and research- Jonathan Han, MD 2016 Press Club of Western Pennsylvania Golden ers are making to turn the tide of this epidemic, UPMC St. Margaret New Kensington Quill Award for Education Feature & Ray Sprigle Memorial Award for Magazines there was one stark omission: providing access to Family Health Center Cara Masset, “Inside the World of OCD” the lifesaving drug naloxone. Recent legislation and efforts by public health Alice Bell 2016 Press Club of Western Pennsylvania Golden departments across the country are facilitating Prevention Point Pittsburgh Quill Award Finalist, Health/Science/Environment naloxone distribution, Story, Online decreasing overdose Thank you for pointing out our omission. Cami Mesa and Elaine Vitone, and death, and improv- Our writer did originally include mention “Second Lives: A Pitt Medcast” ing awareness. Our of naxolone in her draft to us. It was delet- own Southwestern ed because of an editorial oversight. CORRESPONDENCE Pennsylvania leader We gladly receive letters (which we may edit in overdose preven- MOST POPULAR for length, style, and clarity).
  • LONG-TERM MEMBERS 25+ Years of Membership

    LONG-TERM MEMBERS 25+ Years of Membership

    LONG-TERM MEMBERS 25+ Years of Membership Stuart A. Aaronson, MD Stephen P. Ackland, MBBS Carol Aghajanian, MD Steven A. Akman, MD Icahn School of Medicine at Mount Sinai University of Newcastle Memorial Sloan Kettering Cancer Center Roper St. Francis Healthcare United States Australia United States United States Active Member Active Member Active Member Active Member 38 Years of Membership 33 Years of Membership 27 Years of Membership 35 Years of Membership Cory Abate-Shen, PhD Edward M. Acton, PhD Irina U. Agoulnik, PhD Emmanuel T. Akporiaye, PhD Columbia University Irving Medical United States Florida International University Verana Therapeutics Center Emeritus Member United States United States United States 42 Years of Membership Active Member Emeritus Member Active Member 25 Years of Membership 31 Years of Membership 26 Years of Membership David J. Adams, PhD Duke University Medical Center Imran Ahmad, PhD Ala-Eddin Al Moustafa, PhD James L. Abbruzzese, MD United States Northwestern Medicine McGill University Duke University Emeritus Member United States Canada United States 32 Years of Membership Active Member Active Member Active Member 25 Years of Membership 26 Years of Membership 32 Years of Membership Gregory P. Adams, PhD Elucida Oncology Nihal Ahmad, PhD Abdul Al Saadi, PhD Ehtesham A. Abdi, MBBS United States Univ. of Wisconsin Madison Sch. of Med. William Beaumont Hospital The Tweed Hospital Active Member & Public Health United States Australia 29 Years of Membership United States Emeritus Member Emeritus Member Active Member 52 Years of Membership 33 Years of Membership Lucile L. Adams-Campbell, PhD 25 Years of Membership Georgetown Lombardi Comprehensive Suresh K.